Cannabis Stocks: 3 Things to Know Before Buying

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) and Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) are cannabis stocks that are showing some weakness recently, as results disappoint and earnings estimates are ratcheted down.

| More on:
Man holding magnifying glass over a document

Image source: Getty Images.

Recent market action has shown that at least some cannabis stocks may be taking a breather. And while past performance in certainly exceptional, we need to focus on what we can expect for future performance.

Canopy Growth (TSX:WEED)(NYSE:CGC) stock is down 6% in the last month and Cronos Group (TSX:CRON)(NASDAQ:CRON) stock is down 21%.

Let’s look at three things you should think about before buying.

Big expectations are baked in

The expectations baked into cannabis stocks are big — so big that it is beyond reason, with most of them trading well beyond 100 times sales and at price-to-earnings multiples that are equally lofty.

Should marijuana companies disappoint from an earnings or sales perspective, the downside is pretty huge.

I like to minimize my downside and focus on preservation of capital, so given this, these stocks look pretty unattractive to me.

Estimates falling

I know the argument that we should not be looking at earnings in such a high-growth industry that has a huge addressable market, but the fact is that these companies can only lose money for so long before they get into trouble.

For Canopy, consensus earnings estimates in the next two years have come down significantly.  For this year, prior expectations were calling for a loss of $1.47 per share; they are now calling for a loss of $1.78 per share — that’s 21% lower and pretty significant.

2020 and 2021 estimates have fallen significantly as well, which speaks to the lack of visibility and the over-optimism that exists.

Cronos Group stock opened down on the day of its fourth-quarter earnings release, as the company reported fourth-quarter 2018 results that showed a net loss of $11.6 million, or $0.06 per share, compared to a profit of $2.1 million, or $0.01 per share, in the same period last year, as soaring costs take their toll.

Just as important, revenue came in at $5.6 million, up from $1.6 million last year, but well below expectations.

So, for now, marijuana companies have sustained this, but looking ahead we can see that big investments in their businesses are still needed and a lot of the details, such as price, black market sales, and the ability to supply the market at these levels, remain fraught with uncertainty.

We have seen equity investors already pour in huge sums of cash into these companies, and we have seen the dilution that it has brought to existing shareholders.

Huge market

I would like to close this article off with the good news.

The cannabis industry remains a huge industry with a large addressable market.

With estimates putting the market size at up to $150 billion, it is clear that this is a staggering number that will leave many companies and investors far richer than they could have ever imagined.

And it will leave many of the buyers of marijuana to ease their medical symptoms in a far better place.

The transformational qualities of this industry are far-reaching and here to stay.

From an investor viewpoint, the stocks are highly volatile and lack visibility, so I remain cautious.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »